Literature DB >> 19193441

In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.

Philemon Sirven1, Florence Anne Castelli, Alicia Probst, Natacha Szely, Bernard Maillere.   

Abstract

Subunit vaccine candidates against poxvirus infection induced protective humoral and cellular response in animal models but their immunogenicity in human remains unknown. We have therefore evaluated in vitro the CD4 T cell response of the major antigens B5R and A33R and characterized their CD4 T cell epitopes. Twelve peptides selected on the basis of their binding capacity to HLA-DR molecules, induced CD4 T lymphocytes harvested in healthy donors. In the A33R proteins two peptides are T cell stimulating for at least half of the donors and are restricted to multiple HLA-DR molecules in agreement with their broad specificity for HLA-DR molecules. In B5R, two peptides exhibited a good immunoprevalence but only one is a good binder to multiple HLA-DR molecules. One peptide was a moderate binder for multiple HLA-DR molecules, although it was efficiently presented to peptide-specific T cell lines. Altogether, our data demonstrated the capacity of B5R and A33R peptides to elicit a T cell response in multiple healthy donors and showed that promiscuity and immunoprevalence of CD4 T cell epitopes are not necessarily associated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193441     DOI: 10.1016/j.molimm.2008.12.016

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Authors:  Jeffrey S Kennedy; Marc Gurwith; Cornelia L Dekker; Sharon E Frey; Kathryn M Edwards; Julie Kenner; Michael Lock; Cyril Empig; Shigeru Morikawa; Masayuki Saijo; Hiroyuki Yokote; Kevin Karem; Inger Damon; Mark Perlroth; Richard N Greenberg
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

2.  Specificities of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction.

Authors:  Julia Schwaiger; Judith H Aberle; Karin Stiasny; Bernhard Knapp; Wolfgang Schreiner; Ingrid Fae; Gottfried Fischer; Ondrej Scheinost; Vaclav Chmelik; Franz X Heinz
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

3.  The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Authors:  Richard B Kennedy; Gregory A Poland
Journal:  Virology       Date:  2010-10-18       Impact factor: 3.616

4.  CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.

Authors:  Liusong Yin; J Mauricio Calvo-Calle; John Cruz; Frances K Newman; Sharon E Frey; Francis A Ennis; Lawrence J Stern
Journal:  J Immunol       Date:  2013-05-10       Impact factor: 5.422

Review 5.  The immunology of smallpox vaccines.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Curr Opin Immunol       Date:  2009-06-11       Impact factor: 7.486

6.  Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.

Authors:  Nir Paran; Shlomo Lustig; Anat Zvi; Noam Erez; Tomer Israely; Sharon Melamed; Boaz Politi; David Ben-Nathan; Paula Schneider; Batel Lachmi; Ofir Israeli; Dana Stein; Reuven Levin; Udy Olshevsky
Journal:  Virol J       Date:  2013-07-10       Impact factor: 4.099

7.  Human CD4 T cell epitopes selective for Vaccinia versus Variola virus.

Authors:  Alicia Probst; Aurore Besse; Emmanuel Favry; Gilles Imbert; Valérie Tanchou; Florence Anne Castelli; Bernard Maillere
Journal:  Mol Immunol       Date:  2012-11-10       Impact factor: 4.174

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.